Elicio Therapeutics (ELTX) vs Spero Therapeutics (SPRO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Spero Therapeutics (SPRO) has outperformed Elicio Therapeutics (ELTX) over the past year, losing 67.9% versus a loss of 82.8%. Over five years, SPRO leads with a -95.1% price change compared with -96.1% for ELTX. Spero Therapeutics is the larger company by market cap ($43.2 million vs $41.0 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ELTX | SPRO |
|---|---|---|
| Share price | $1.45 | $0.742 |
| Market cap | $41.05M | $43.23M |
| 1-day change | -3.33% | -10.20% |
| YTD return | -81.78% | -68.15% |
| 1-year return | -82.84% | -67.88% |
| 5-year return | -96.13% | -95.09% |
| EPS (TTM) | $-1.81 | $-0.50 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | — | $66.80M |
| Revenue growth (YoY) | — | +39.24% |
| Net income (latest FY) | $-39.57M | $8.57M |
| Operating margin | — | 9.45% |
| Net margin | — | 12.83% |
| 52-week high | $16.00 | $3.08 |
| 52-week low | $1.25 | $0.73 |
| Distance from 52-week high | -90.94% | -75.91% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +842.76% | +573.85% |
| Average volume | 324.71K | 530.46K |
| Shares outstanding | 28.31M | 58.26M |
| Employees | 33 | 25 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- SPRO has outperformed ELTX by 15.0 percentage points over the past year.
About Elicio Therapeutics
ELTX stock →Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops immunotherapies for the treatment of cancer. Its lead product candidate, ELI-002, is a multivalent lymph node-targeted amphiphile (AMP) peptide vaccine that is in Phase II clinical trials for seven Kirsten rat sarcoma viral oncogene homolog driver mutations.
Health Care · Biotechnology: Pharmaceutical Preparations · 33 employees
About Spero Therapeutics
SPRO stock →Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company's product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which has completed second Phase 3 trial.
Health Care · Biotechnology: Pharmaceutical Preparations · 25 employees
ELTX vs SPRO FAQ
Which is bigger, Elicio Therapeutics or Spero Therapeutics?
Spero Therapeutics (SPRO) is larger, with a market capitalization of $43.23M compared with $41.05M for Elicio Therapeutics (ELTX).
Which stock has performed better over the past year, ELTX or SPRO?
SPRO returned -67.88% over the past 12 months, compared with -82.84% for ELTX (price return, excluding dividends). Past performance does not predict future results.
Are Elicio Therapeutics and Spero Therapeutics in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.